Hemostatic Alterations in Liver Disease and Liver Transplantation

Consultative Hemostasis and Thrombosis

Volumn , Issue , 2007, Pages 647-659

  Senzolo, Marco ^a   Burroughs, Andrew K ^b,c  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 58149350546     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-141602401-9.10039-2     Document Type: Chapter

References (193)

1. T Lisman, FW Leebeek and PG de Groot (2002) Haemostatic abnormalities in patients with liver disease. J Hepatol 37 280-287.
2. SI Rapaport (2000) Coagulation problems in liver disease. Blood Coagul Fibrinolysis 11(suppl 1), S69-S74.
3. A Tripodi, F Salerno, V Chantarangkul, et al. (2005) Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 41 553-558.
4. DA Kelly and JA Summerfield (1987) Hemostasis in liver disease. Semin Liver Dis 7 182-191.
5. D Ferro, C Quintarelli, A Lattuada, et al. (1996) High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: Relationship to endotoxemia. Hepatology 23 1377-1383.
6. KL Wion, D Kelly, JA Summerfield, et al. (1985) Distribution of factor VIII mRNA and antigen in human liver and other tissues. Nature 317 726-729.
7. MJ Hollestelle, HG Geertzen, IH Straatsburg, et al. (2004) Factor VIII expression in liver disease. Thromb Haemost 91 267-275.
8. MJ Hollestelle, T Thinnes, K Crain, et al. (2001) Tissue distribution of factor VIII gene expression in vivo: A closer look. Thromb Haemost 86 855-861.
9. R Kerr (2003) New insights into haemostasis in liver failure. Blood Coagul Fibrinolysis 14(Suppl 1), S43-S45.
10. P Maisonneuve and Y Sultan (1977) Modification of factor VIII complex properties in patients with liver disease. J Clin Pathol 30 221-227.
11. MM Mueller, B Bomke and E Seifried (2002) Fresh frozen plasma in patients with disseminated intravascular coagulation or in patients with liver diseases. Thromb Res 107(Suppl 1), S9-S17.
12. RA Blanchard, BC Furie, M Jorgensen, et al. (1981) Acquired vitamin K‐dependent carboxylation deficiency in liver disease. N Engl J Med 305 242-248.
13. M Belle, R Brebant, R Guinet, et al. (1995) Production of a new monoclonal antibody specific to human des‐gamma‐carboxyprothrombin in the presence of calcium ions: Application to the development of a sensitive ELISA‐test. J Immunoassay 16 213-229.
14. S Sherlock and J Dooley (2002) The haematology of liver disease. S Sherlock, J Dooley (Eds) Diseases of the Liver and Biliary System Oxford: Blackwell Publishing 47-64.
15. SP Pereira, D Rowbotham, S Fitt, et al. (2005) Pharmacokinetics and efficacy of oral versus intravenous mixed‐micellar phylloquinone (vitamin K 1) in severe acute liver disease. J Hepatol 42 365-370.
16. R Kerr, P Newsome, L Germain, et al. (2003) Effects of acute liver injury on blood coagulation. J Thromb Haemost 1 754-759.
17. IC Weitz and HA Liebman (1993) Des‐gamma‐carboxy (abnormal) prothrombin and hepatocellular carcinoma: A critical review. Hepatology 18 990-997.
18. L Amitrano, V Brancaccio, MA Guardascione, et al. (2000) Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis. Hepatology 31 345-348.
19. M Senzolo, CE Cholongitas, D Patch, et al. (2005) Update on the classification, assessment of prognosis and therapy of Budd‐Chiari syndrome. Nat Clin Pract Gastroenterol Hepatol 2 182-190.
20. M Primignani, I Martinelli, P Bucciarelli, et al. (2005) Risk factors for thrombophilia in extrahepatic portal vein obstruction. Hepatology 41 603-608.
21. Y Baruch, K Neubauer, A Ritzel, et al. (2004) Von Willebrand gene expression in damaged human liver. Hepatogastroenterology 51 684-688.
22. G Escolar, A Cases, M Vinas, et al. (1999) Evaluation of acquired platelet dysfunctions in uremic and cirrhotic patients using the platelet function analyzer (PFA‐100): Influence of hematocrit elevation. Haematologica 84 614-619.
23. DA Kelly and EG Tuddenham (1986) Haemostatic problems in liver disease. Gut 27 339-349.
24. L Albornoz, D Alvarez, JC Otaso, et al. (1999) Von Willebrand factor could be an index of endothelial dysfunction in patients with cirrhosis: Relationship to degree of liver failure and nitric oxide levels. J Hepatol 30 451-455.
25. K Lechner, H Niessner and E Thaler (1977) Coagulation abnormalities in liver disease. Semin Thromb Hemost 4 40-56.
26. IW Dymock, JS Tucker, IL Woolf, et al. (1975) Coagulation studies as a prognostic index in acute liver failure. Br J Haematol 29 385-395.
27. JL Francis and DJ Armstrong (1982) Fibrinogen‐bound sialic acid levels in the dysfibrinogenaemia of liver disease. Haemostasis 11 215-222.
28. RD Barr, M Allardyce, PW Brunt, et al. (1978) Dysfibrinogenaemia and liver cell growth. J Clin Pathol 31 89-92.
29. H Noguchi, K Hirai, Y Aoki, et al. (1995) Changes in platelet kinetics after a partial splenic arterial embolization in cirrhotic patients with hypersplenism. Hepatology 22 1682-1688.
30. Y Sohma, H Akahori, N Seki, et al. (1994) Molecular cloning and chromosomal localization of the human thrombopoietin gene. FEBS Lett 353 57-61.
31. K Yanaga, AG Tzakis, M Shimada, et al. (1989) Reversal of hypersplenism following orthotopic liver transplantation. Ann Surg 210 180-183.
32. PA Clavien, CA Camargo Jr, R Croxford, et al. (1994) Definition and classification of negative outcomes in solid organ transplantation: Application in liver transplantation. Ann Surg 220 109-120.
33. E Giannini, F Botta, P Borro, et al. (2003) Platelet count/spleen diameter ratio: Proposal and validation of a non‐invasive parameter to predict the presence of oesophageal varices in patients with liver cirrhosis. Gut 52 1200-1205.
34. SC Robson, D Kahn, J Kruskal, et al. (1993) Disordered hemostasis in extrahepatic portal hypertension. Hepatology 18 853-857.
35. A Panasiuk, D Prokopowicz, J Zak, et al. (2004) Reticulated platelets as a marker of megakaryopoiesis in liver cirrhosis. Relation to thrombopoietin and hepatocyte growth factor serum concentration. Hepatogastroenterology 51 1124-1128.
36. W Jelkmann (2001) The role of the liver in the production of thrombopoietin compared with erythropoietin. Eur J Gastroenterol Hepatol 13 791-801.
37. K Kitano, S Shimodaira, T Ito, et al. (1999) Liver cirrhosis with marked thrombocytopenia and highly elevated serum thrombopoietin levels. Int J Hematol 70 52-55.
38. TG Martin 3rd, KA Somberg, YG Meng, et al. (1997) Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation. Ann Intern Med 127 285-288.
39. GL Wang, BH Jiang, EA Rue, et al. (1995) Hypoxia‐inducible factor 1 is a basic‐helix‐loop‐helix‐PAS heterodimer regulated by cellular O 2 tension. Proc Natl Acad Sci USA 92 5510-5514.
40. T Nagamine, T Ohtuka, K Takehara, et al. (1996) Thrombocytopenia associated with hepatitis C viral infection. J Hepatol 24 135-140.
41. M Peck‐Radosavljevic (2000) Thrombocytopenia in liver disease. Can J Gastroenterol 14(Suppl D), 60D-66D.
42. F Violi, R Leo, S Basili, et al. (1994) Association between prolonged bleeding time and gastrointestinal hemorrhage in 102 patients with liver cirrhosis: Results of a retrospective study. Haematologica 79 61-65.
43. F Violi, D Ferro, S Basili, et al. (1992) Hyperfibrinolysis increases the risk of gastrointestinal hemorrhage in patients with advanced cirrhosis. Hepatology 15 672-676.
44. M Kajihara, S Kato, Y Okazaki, et al. (2003) A role of autoantibody‐mediated platelet destruction in thrombocytopenia in patients with cirrhosis. Hepatology 37 1267-1276.
45. SM Feistauer, E Penner, WR Mayr, et al. (1997) Target platelet antigens of autoantibodies in patients with primary biliary cirrhosis. Hepatology 25 1343-1345.
46. G Escolar, A Cases, M Vinas, et al. (1999) Evaluation of acquired platelet dysfunctions in uremic and cirrhotic patients using the platelet function analyzer (PFA‐100): Influence of hematocrit elevation. Haematologica 84 614-619.
47. G Laffi, F Marra, P Gresele, et al. (1992) Evidence for a storage pool defect in platelets from cirrhotic patients with defective aggregation. Gastroenterology 103 641-646.
48. HM Younger, PW Hadoke, JF Dillon, et al. (1997) Platelet function in cirrhosis and the role of humoral factors. Eur J Gastroenterol Hepatol 9 989-992.
49. JS Owen, RA Hutton, RC Day, et al. (1981) Platelet lipid composition and platelet aggregation in human liver disease. J Lipid Res 22 423-430.
50. DR Riddell and JS Owen (1999) Nitric oxide and platelet aggregation. Vitam Horm 57 25-48.
51. Z Ben Ari, M Panagou, D Patch, et al. (1997) Hypercoagulability in patients with primary biliary cirrhosis and primary sclerosing cholangitis evaluated by thrombelastography. J Hepatol 26 554-559.
52. R Pihusch, A Rank, P Gohring, et al. (2002) Platelet function rather than plasmatic coagulation explains hypercoagulable state in cholestatic liver disease. J Hepatol 37 548-555.
53. N Salooja and DJ Perry (2001) Thrombelastography. Blood Coagul Fibrinolysis 12 327-337.
54. M Bolognesi, C Merkel, D Sacerdoti, et al. (2002) Role of spleen enlargement in cirrhosis with portal hypertension. Dig Liver Dis 34 144-150.
55. G N'Kontchou, O Seror, V Bourcier, et al. (2005) Partial splenic embolization in patients with cirrhosis: Efficacy, tolerance and long‐term outcome in 32 patients. Eur J Gastroenterol Hepatol 17 179-184.
56. N Jabbour, A Zajko, P Orons, et al. (1998) Does transjugular intrahepatic portosystemic shunt (TIPS) resolve thrombocytopenia associated with cirrhosis? Dig Dis Sci 43 2459-2462.
57. Z Karasu, A Gurakar, B Kerwin, et al. (2000) Effect of transjugular intrahepatic portosystemic shunt on thrombocytopenia associated with cirrhosis. Dig Dis Sci 45 1971-1976.
58. HG Schipper and JW ten Cate (1982) Antithrombin III transfusion in patients with hepatic cirrhosis. Br J Haematol 52 25-33.
59. HA Liebman, WG McGehee, MJ Patch, et al. (1983) Severe depression of antithrombin III associated with disseminated intravascular coagulation in women with fatty liver of pregnancy. Ann Intern Med 98 330-333.
60. F Carmassi, M Morale, F De Negri, et al. (1995) Modulation of hemostatic balance with antithrombin III replacement therapy in a case of liver cirrhosis associated with recurrent venous thrombosis. J Mol Med 73 89-93.
61. DS Fair and RA Marlar (1986) Biosynthesis and secretion of factor VII, protein C, protein S, and the Protein C inhibitor from a human hepatoma cell line. Blood 67 64-70.
62. PM Mannucci and S Vigano (1982) Deficiencies of protein C, an inhibitor of blood coagulation. Lancet 2 463-467.
63. MC Minnema, HL Janssen, P Niermeijer, et al. (2000) Budd‐Chiari syndrome: Combination of genetic defects and the use of oral contraceptives leading to hypercoagulability. J Hepatol 33 509-512.
64. M Primignani, I Martinelli, P Bucciarelli, et al. (2005) Risk factors for thrombophilia in extrahepatic portal vein obstruction. Hepatology 41 603-608.
65. M Bhattacharyya, G Makharia, M Kannan, et al. (2004) Inherited prothrombotic defects in Budd‐Chiari syndrome and portal vein thrombosis: A study from North India. Am J Clin Pathol 121 844-847.
66. SF Stein and LA Harker (1982) Kinetic and functional studies of platelets, fibrinogen, and plasminogen in patients with hepatic cirrhosis. J Lab Clin Med 99 217-230.
67. FW Leebeek, C Kluft, EA Knot, et al. (1989) Histidine‐rich glycoprotein is elevated in mild liver cirrhosis and decreased in moderate and severe liver cirrhosis. J Lab Clin Med 113 493-497.
68. L Biland, F Duckert, S Prisender, et al. (1989) Quantitative estimation of coagulation factors in liver disease: The diagnostic and prognostic value of factor XIII, factor V, and plasminogen. Thromb Haemost 39 646-656.
69. SL Hersch, T Kunelis and RB Francis Jr (1987) The pathogenesis of accelerated fibrinolysis in liver cirrhosis: A critical role for tissue plasminogen activator inhibitor. Blood 69 1315-1319.
70. JR Pernambuco, PG Langley, RD Hughes, et al. (1993) Activation of the fibrinolytic system in patients with fulminant liver failure. Hepatology 18 1350-1356.
71. KQ Hu, AS Yu, L Tiyyagura, et al. (2001) Hyperfibrinolytic activity in hospitalized cirrhotic patients in a referral liver unit. Am J Gastroenterol 96 1581-1586.
72. S Agarwal, KA Joyner Jr and MW Swaim (2000) Ascites fluid as a possible origin for hyperfibrinolysis in advanced liver disease. Am J Gastroenterol 95 3218-3224.
73. JA Paramo and E Rocha (1993) Hemostasis in advanced liver disease. Semin Thromb Hemost 19 184-190.
74. Z Ben Ari, E Osman, RA Hutton, et al. (1999) Disseminated intravascular coagulation in liver cirrhosis: Fact or fiction? Am J Gastroenterol 94 2977-2982.
75. PC Comp, RM Jacocks, C Rubenstein, et al. (1981) A lysine‐absorbable plasminogen activator is elevated in conditions associated with increased fibrinolytic activity. J Lab Clin Med 97 637-645.
76. RB Francis Jr and DI Feinstein (1984) Clinical significance of accelerated fibrinolysis in liver disease. Haemostasis 14 460-465.
77. T Lisman, FW Leebeek, LO Mosnier, et al. (2001) Thrombin‐activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology 121 131-139.
78. M Colucci, BM Binetti, MG Branca, et al. (2003) Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. Hepatology 38 230-237.
79. F Piscaglia, S Siringo, RC Hermida, et al. (2000) Diurnal changes of fibrinolysis in patients with liver cirrhosis and esophageal varices. Hepatology 31 349-357.
80. JH Lewis, FA Bontempo, SA Awad, et al. (1989) Liver transplantation: Intraoperative changes in coagulation factors in 100 first transplants. Hepatology 9 710-714.
81. H Segal, S Cottam, D Potter, et al. (1997) Coagulation and fibrinolysis in primary biliary cirrhosis compared with other liver disease and during orthotopic liver transplantation. Hepatology 25 683-688.
82. L Amitrano, MA Guardascione, V Brancaccio, et al. (2002) Coagulation disorders in liver disease. Semin Liver Dis 22 83-96.
83. JM Carr (1989) Disseminated intravascular coagulation in cirrhosis. Hepatology 10 103-110.
84. F Violi, D Ferro, S Basili, et al. (1995) Association between low‐grade disseminated intravascular coagulation and endotoxemia in patients with liver cirrhosis. Gastroenterology 109 531-539.
85. B Kemkes‐Matthes, H Bleyl and KJ Matthes (1991) Coagulation activation in liver diseases. Thromb Res 64 253-261.
86. JH Joist (1999) AICF and DIC in liver cirrhosis: Expressions of a hypercoagulable state. Am J Gastroenterol 94 2801-2803.
87. S Basili, D Ferro and F Violi (1999) Endotoxaemia, hyperfibrinolysis, and bleeding in cirrhosis. Lancet 353 1102.
88. RC Botero and MR Lucey (2003) Organ allocation: model for end‐stage liver disease, Child‐Turcotte‐Pugh, Mayo risk score, or something else. Clin Liver Dis 7 715-727.
89. PS Kamath, RH Wiesner, M Malinchoc, et al. (2001) A model to predict survival in patients with end‐stage liver disease. Hepatology 33 464-470.
90. H Bismuth, D Samuel, D Castaing, et al. (1995) Orthotopic liver transplantation in fulminant and subfulminant hepatitis: The Paul Brousse experience. Ann Surg 222 109-119.
91. A Pauwels, N Mostefa‐Kara, C Florent, et al. (1993) Emergency liver transplantation for acute liver failure: Evaluation of London and Clichy criteria. J Hepatol 17 124-127.
92. JG O'Grady, GJ Alexander, KM Hayllar, et al. (1989) Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 97 439-445.
93. F Violi, D Ferro, S Basili, et al. (1995) Prognostic value of clotting and fibrinolytic systems in a follow‐up of 165 liver cirrhotic patients: CALC Group. Hepatology 22 96-100.
94. A Gutierrez, J Sanchez‐Paya, P Marco, et al. (2001) Prognostic value of fibrinolytic tests for hospital outcome in patients with acute upper gastrointestinal hemorrhage. J Clin Gastroenterol 32 315-318.
95. IR Wanless, F Wong, LM Blendis, et al. (1995) Hepatic and portal vein thrombosis in cirrhosis: Possible role in development of parenchymal extinction and portal hypertension. Hepatology 21 1238-1247.
96. L Amitrano, MA Guardascione, V Brancaccio, et al. (2004) Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol 40 736-741.
97. C Francoz, J Belghiti, V Vilgrain, et al. (2005) Splanchnic vein thrombosis in candidates for liver transplantation: Usefulness of screening and anticoagulation. Gut 54 691-697.
98. JD Espiritu (2000) Pulmonary embolism in a patient with coagulopathy from end‐stage liver disease. Chest 117 924-925.
99. B Condat, F Pessione, DM Helene, et al. (2000) Recent portal or mesenteric venous thrombosis: Increased recognition and frequent recanalization on anticoagulant therapy. Hepatology 32 466-470.
100. CS Kitchens, MH Weidner and R Lottenberg (2007) Chronic oral anticoagulant therapy for extrahepatic visceral thrombosis is safe. J Thromb Thrombolysis 23 223-228.
101. SH Caldwell, M Hoffman, T Lisman, et al. (2006) Coagulation disorders and hemostasis in liver disease: Pathophysiology and critical assessment of current management. Hepatology 44 1039-1046.
102. F Violl, S Basili, D Ferro, et al. (1996) Association between high values of D‐dimer and tissue‐plasminogen activator activity and first gastrointestinal bleeding in cirrhotic patients: CALC Group. Thromb Haemost 76 177-183.
103. J Goulis, D Patch and AK Burroughs (1999) Bacterial infection in the pathogenesis of variceal bleeding. Lancet 353 139-142.
104. TN Chau, YW Chan, D Patch, et al. (1998) Thrombelastographic changes and early rebleeding in cirrhotic patients with variceal bleeding. Gut 43 267-271.
105. P Montalto, J Vlachogiannakos, DJ Cox, et al. (2002) Bacterial infection in cirrhosis impairs coagulation by a heparin effect: A prospective study. J Hepatol 37 463-470.
106. L Perkins, M Jeffries and T Patel (2004) Utility of preoperative scores for predicting morbidity after cholecystectomy in patients with cirrhosis. Clin Gastroenterol Hepatol 2 1123-1128.
107. T Patel (1999) Surgery in the patient with liver disease. Mayo Clin Proc 74 593-599.
108. LS Friedman (1999) The risk of surgery in patients with liver disease. Hepatology 29 1617-1623.
109. RN Garrison, HM Cryer, DA Howard, et al. (1984) Clarification of risk factors for abdominal operations in patients with hepatic cirrhosis. Ann Surg 199 648-655.
110. K Tsuji, Y Eguchi and M Kodama (1996) Postoperative hypercoagulable state followed by hyperfibrinolysis related to wound healing after hepatic resection. J Am Coll Surg 183 230-238.
111. C Meijer, MJ Wiezer, CE Hack, et al. (2001) Coagulopathy following major liver resection: The effect of rBPI21 and the role of decreased synthesis of regulating proteins by the liver. Shock 15 261-271.
112. K Ewe (1981) Bleeding after liver biopsy does not correlate with indices of peripheral coagulation. Dig Dis Sci 26 388-393.
113. AK Burroughs and L Dagher (2002) Liver biopsy. Gastroenterological Endoscopy New York: Thieme 252-259.
114. A Grant and J Neuberger (1999) Guidelines on the use of liver biopsy in clinical practice. British Society of Gastroenterology. Gut 45(Suppl 4), IV1-IV11.
115. IT Gilmore, A Burroughs, IM Murray‐Lyon, et al. (1995) Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: An audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut 36 437-441.
116. DB McGill, J Rakela, AR Zinsmeister, et al. (1990) A 21‐year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology 99 1396-1400.
117. JC Blake, D Sprengers, P Grech, et al. (1990) Bleeding time in patients with hepatic cirrhosis. BMJ 301 12-15.
118. GV Papatheodoridis, D Patch, A Watkinson, et al. (1999) Transjugular liver biopsy in the 1990s: A 2‐year audit. Aliment Pharmacol Ther 13 603-608.
119. I Pache and M Bilodeau (2005) Severe haemorrhage following abdominal paracentesis for ascites in patients with liver disease. Aliment Pharmacol Ther 21 525-529.
120. CH Lin, SC Chen and PC Ko (2005) Preprocedure coagulation tests are unnecessary before abdominal paracentesis in emergency departments. Hepatology 41 402-403.
121. BA Runyon (1986) Paracentesis of ascitic fluid: A safe procedure:. Arch Intern Med 146 2259-2261.
122. B Bernard, JD Grange, EN Khac, et al. (1999) Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: A meta‐analysis. Hepatology 29 1655-1661.
123. J Goulis, A Armonis, D Patch, et al. (1998) Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. Hepatology 27 1207-1212.
124. B Bernard, JF Cadranel, D Valla, et al. (1995) Prognostic significance of bacterial infection in bleeding cirrhotic patients: A prospective study. Gastroenterology 108 1828-1834.
125. MC Hou, HC Lin, TT Liu, et al. (2004) Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: A randomized trial. Hepatology 39 746-753.
126. A Zambruni, U Thalheimer, J Coppell, et al. (2004) Endogenous heparin‐like activity detected by anti‐Xa assay in infected cirrhotic and non‐cirrhotic patients. Scand J Gastroenterol 39 830-836.
127. U Thalheimer, C Triantos, D Samonakis, et al. (2005) Endogenous heparinoids in acute variceal bleeding. Gut 54 310-311.
128. RF McKee, S Hodson, J Dawes, et al. (1992) Plasma concentrations of endogenous heparinoids in portal hypertension. Gut 33 1549-1552.
129. U Thalheimer, CK Triantos, DN Samonakis, et al. (2005) Infection, coagulation, and variceal bleeding in cirrhosis. Gut 54 556-563.
130. G Grignani and A Maiolo (2000) Cytokines and hemostasis. Haematologica 85 967-972.
131. A Plessier, MH Denninger, Y Consigny, et al. (2003) Coagulation disorders in patients with cirrhosis and severe sepsis. Liver Int 23 440-448.
132. F Wong, M Bernardi, R Balk, et al. (2005) Sepsis in cirrhosis: Report on the 7th meeting of the International Ascites Club. Gut 54 718-725.
133. GT Everson (1997) A hepatologist's perspective on the management of coagulation disorders before liver transplantation. Liver Transpl Surg 3 646-652.
134. DJ Martin, CE Lucas, AM Ledgerwood, et al. (1985) Fresh frozen plasma supplement to massive red blood cell transfusion. Ann Surg 202 505-511.
135. GS Maltz, JE Siegel and JL Carson (2000) Hematologic management of gastrointestinal bleeding. Gastroenterol Clin North Am 29 169-187.
136. P Gunter (1996) Practice guidelines for blood component therapy. Anesthesiology 85 1219-1220.
137. EF Mammen (2000) Disseminated intravascular coagulation (DIC). Clin Lab Sci 13 239-245.
138. CJ French, R Bellomo and P Angus (2003) Cryoprecipitate for the correction of coagulopathy associated with liver disease. Anaesth Intensive Care 31 357-361.
139. PM Mannucci, MT Canciani, L Rota, et al. (1981) Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects and patients with haemophilia A and von Willebrand's disease. Br J Haematol 47 283-293.
140. AK Burroughs, K Matthews, M Qadiri, et al. (1985) Desmopressin and bleeding time in patients with cirrhosis. Br Med J (Clin Res Ed) 291 1377-1381.
141. R de Franchis, PG Arcidiacono, L Carpinelli, et al. (1993) Randomized controlled trial of desmopressin plus terlipressin vs terlipressin alone for the treatment of acute variceal hemorrhage in cirrhotic patients: A multicenter, double‐blind study. New Italian Endoscopic Club. Hepatology 18 1102-1107.
142. AY Wong, MG Irwin, TW Hui, et al. (2003) Desmopressin does not decrease blood loss and transfusion requirements in patients undergoing hepatectomy. Can J Anaesth 50 14-20.
143. R Egbring, R Seitz, H Blanke, et al. (1986) The proteinase inhibitor complexes (antithrombin III‐thrombin, alpha 2antiplasmin‐plasmin and alpha 1antitrypsin‐elastase) in septicemia, fulminant hepatic failure and cardiac shock: Value for diagnosis and therapy control in DIC/F syndrome. Behring Inst Mitt 87-103.
144. G Palareti, C Legnani, M Maccaferri, et al. (1991) Coagulation and fibrinolysis in orthotopic liver transplantation: Role of the recipient's disease and use of antithrombin III concentrates S. Orsola Working Group on Liver Transplantation. Haemostasis 21 68-76.
145. SH Caldwell, C Chang and BG Macik (2004) Recombinant activated factor VII (rFVIIa) as a hemostatic agent in liver disease: A break from convention in need of controlled trials. Hepatology 39 592-598.
146. DE Bernstein, L Jeffers, E Erhardtsen, et al. (1997) Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: A preliminary study. Gastroenterology 113 1930-1937.
147. CM Lindley, WT Sawyer, BG Macik, et al. (1994) Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 55 638-648.
148. L Jeffers, N Chalasani, L Balart, et al. (2002) Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy. Gastroenterology 123 118-126.
149. A Chuansumrit, S Treepongkaruna and P Phuapradit (2001) Combined fresh frozen plasma with recombinant factor VIIa in restoring hemostasis for invasive procedures in children with liver diseases. Thromb Haemost 85 748-749.
150. J Bosch, D Thabut, F Bendtsen, et al. (2004) Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: A randomized, double‐blind trial. Gastroenterology 127 1123-1130.
151. E Ejlersen, T Melsen, J Ingerslev, et al. (2001) Recombinant activated factor VII (rFVIIa) acutely normalizes prothrombin time in patients with cirrhosis during bleeding from oesophageal varices. Scand J Gastroenterol 36 1081-1085.
152. R Romero‐Castro, M Jimenez‐Saenz, F Pellicer‐Bautista, et al. (2004) Recombinant‐activated factor VII as hemostatic therapy in eight cases of severe hemorrhage from esophageal varices. Clin Gastroenterol Hepatol 2 78-84.
153. SS Shapiro (2003) Treating thrombosis in the 21st century. N Engl J Med 349 1762-1764.
154. YG Kang, DJ Martin, J Marquez, et al. (1985) Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantation. Anesth Analg 64 888-896.
155. JC Palomo Sanchez, C Jimenez, GE Moreno, et al. (1998) Effects of intraoperative blood transfusion on postoperative complications and survival after orthotopic liver transplantation. Hepatogastroenterology 45 1026-1033.
156. A Steib, G Freys, C Lehmann, et al. (2001) Intraoperative blood losses and transfusion requirements during adult liver transplantation remain difficult to predict. Can J Anaesth 48 1075-1079.
157. A Steib, N Gengenwin, G Freys, et al. (1994) Predictive factors of hyperfibrinolytic activity during liver transplantation in cirrhotic patients. Br J Anaesth 73 645-648.
158. HG Hendriks, MJ van der, IJ Klompmaker, et al. (2000) Blood loss in orthotopic liver transplantation: A retrospective analysis of transfusion requirements and the effects of autotransfusion of cell saver blood in 164 consecutive patients. Blood Coagul Fibrinolysis 11(Suppl 1), S87-S93.
159. RM Kirby, P McMaster, D Clements, et al. (1987) Orthotopic liver transplantation: Postoperative complications and their management. Br J Surg 74 3-11.
160. M Carlier, LJ Van Obbergh, F Veyckemans, et al. (1993) Hemostasis in children undergoing liver transplantation. Semin Thromb Hemost 19 218-222.
161. Y Kang (1977) Coagulation and liver transplantation: Current concepts. Liver Transpl Surg 3 465-467.
162. YG Kang, DJ Martin, J Marquez, et al. (1985) Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantation. Anesth Analg 64 888-896.
163. DJ Loskutoff and TE Edgington (1977) Synthesis of a fibrinolytic activator and inhibitor by endothelial cells. Proc Natl Acad Sci U S A 74 3903-3907.
164. JJ Emeis, CM van den Hoogen and D Jense (1985) Hepatic clearance of tissue‐type plasminogen activator in rats. Thromb Haemost 54 661-664.
165. P Kalicinski, A Kaminski, T Drewniak, et al. (1999) Quick correction of hemostasis in two patients with fulminant liver failure undergoing liver transplantation by recombinant activated factor VII. Transplant Proc; 31 378-379.
166. HG Hendriks, K Meijer, JT De Wolf, et al. (2002) Effects of recombinant activated factor VII on coagulation measured by thromboelastography in liver transplantation. Blood Coagul Fibrinolysis 13 309-313.
167. K Meijer, HG Hendriks, JT De Wolf, et al. (2003) Recombinant factor VIIa in orthotopic liver transplantation: Influence on parameters of coagulation and fibrinolysis. Blood Coagul Fibrinolysis 14 169-174.
168. RJ Porte (1993) Coagulation and fibrinolysis in orthotopic liver transplantation: current views and insights. Semin Thromb Hemost 19 191-196.
169. H Riess, M Jochum, W Machleidt, et al. (1991) Possible role of extracellularly released phagocyte proteinases in coagulation disorder during liver transplantation. Transplantation 52 482-484.
170. DE Hutchison, E Genton, KA Porter, et al. (1968) Platelet changes following clinical and experimental hepatic homotransplantation. Arch Surg 97 27-33.
171. RJ Porte, EA Knot and FA Bontempo (1989) Hemostasis in liver transplantation. Gastroenterology 97 488-501.
172. D Arnoux, B Boutiere, M Houvenaeghel, et al. (1989) Intraoperative evolution of coagulation parameters and t‐PA/PAI balance in orthotopic liver transplantation. Thromb Res 55 319-328.
173. RJ Porte, FA Bontempo, EA Knot, et al. (1989) Systemic effects of tissue plasminogen activator‐associated fibrinolysis and its relation to thrombin generation in orthotopic liver transplantation. Transplantation 47 978-984.
174. CM Bakker, JD Blankensteijn, P Schlejen, et al. (1994) The effects of long‐term graft preservation on intraoperative hemostatic changes in liver transplantation: A comparison between orthotopic and heterotopic transplantation in the pig. HPB Surg 7 265-280.
175. M Moriau, PJ Kestens and R Masure (1969) Heparin and antifibrinolytic agents during experimental hepatectomy and liver transplantation. Pathol Eur 4 172-182.
176. SA Harding, SV Mallett, TD Peachey, et al. (1997) Use of heparinase modified thrombelastography in liver transplantation. Br J Anaesth 78 175-179.
177. L Shore‐Lesserson (2002) Point‐of‐care coagulation monitoring for cardiovascular patients: Past and present. J Cardiothorac Vasc Anesth 16 99-106.
178. IQ Molenaar, C Legnani, TH Groenland, et al. (2001) Aprotinin in orthotopic liver transplantation: Evidence for a prohemostatic, but not a prothrombotic, effect. Liver Transpl 7 896-903.
179. JY Findlay and RP Kufner (2003) Aprotinin reduces vasoactive medication use during adult liver transplantation. J Clin Anesth 15 19-23.
180. RJ Marcel, WC Stegall, CT Suit, et al. (1996) Continuous small‐dose aprotinin controls fibrinolysis during orthotopic liver transplantation. Anesth Analg 82 1122-1125.
181. RJ Porte, IQ Molenaar, B Begliomini, et al. (2000) Aprotinin and transfusion requirements in orthotopic liver transplantation: A multicentre randomised double‐blind study. EMSALT Study Group. Lancet 355 1303-1309.
182. Y Vater, A Levy, K Martay, et al. (2004) Adjuvant drugs for end‐stage liver failure and transplantation. Med Sci Monit 10 RA77-RA88.
183. M Sopher, M Braunfeld, C Shackleton, et al. (1997) Fatal pulmonary embolism during liver transplantation. Anesthesiology 87 429-432.
184. Y Kang, JH Lewis, A Navalgund, et al. (1987) Epsilon‐aminocaproic acid for treatment of fibrinolysis during liver transplantation. Anesthesiology 66 766-773.
185. A Dalmau, A Sabate, F Acosta, et al. (2000) Tranexamic acid reduces red cell transfusion better than epsilon‐aminocaproic acid or placebo in liver transplantation. Anesth Analg 91 29-34.
186. A Dalmau, A Sabate, M Koo, et al. (2001) Prophylactic use of tranexamic acid and incidence of arterial thrombosis in liver transplantation. Anesth Analg 93 516.
187. A Dalmau, A Sabate, F Acosta, et al. (1999) Comparative study of antifibrinolytic drugs in orthotopic liver transplantation. Transplant Proc 31 2361-2362.
188. A Dalmau, A Sabate, M Koo, et al. (2004) The prophylactic use of tranexamic acid and aprotinin in orthotopic liver transplantation: A comparative study. Liver Transpl 10 279-284.
189. E Cerutti, C Stratta, R Romagnoli, et al. (2004) Thromboelastogram monitoring in the perioperative period of hepatectomy for adult living liver donation. Liver Transpl 10 289-294.
190. EM Richards, GJ Alexander, RY Calne, et al. (1997) Thrombocytopenia following liver transplantation is associated with platelet consumption and thrombin generation. Br J Haematol 98 315-321.
191. M Faeh, SP Hauser and UE Nydegger (2001) Transient thrombopoietin peak after liver transplantation for end‐stage liver disease. Br J Haematol 112 493-498.
192. J Goulis, TN Chau, S Jordan, et al. (1999) Thrombopoietin concentrations are low in patients with cirrhosis and thrombocytopenia and are restored after orthotopic liver transplantation. Gut 44 754-758.
193. DS Sutedja, CT Wai, KF Teoh, et al. (2004) Persistent thrombocytopenia in liver transplant patients. Transplant Proc 36 2331-2333.